A Clinical Study of 6MW3211 Injection to Treat Relapsed/Refractory AML or MDS
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmacodynamics of
6MW3211 injection in subjects with relapsed/refractory AML/MDS，and to find out appropriate
dose level and dose interval for subsequent clinical studies.